{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:21:45Z","timestamp":1792300905015,"version":"4.4.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/jcp.0b013e3182979d32","type":"journal-article","created":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T12:33:09Z","timestamp":1373718789000},"page":"658-666","source":"Crossref","is-referenced-by-count":56,"title":["\u03b11-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans"],"prefix":"10.1097","volume":"33","author":[{"given":"C\u00e9dric M.","family":"Hysek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja E.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D.","family":"Simmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Grouzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of ecstasy 3,4-methylenedioxy-methamphetamine (MDMA): serotonin transporters are targets for MDMA-induced serotonin release.","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","article-title":"MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.","volume":"189","author":"Verrico","year":"2007","journal-title":"Psychopharmacology"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","article-title":"Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are attenuated by the serotonin uptake inhibitor citalopram.","volume":"22","author":"Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1210\/jc.2011-1143","article-title":"Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.","volume":"96","author":"Simmler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (ecstasy) in vitro and in humans in a randomized placebo-controlled laboratory study.","volume":"7","author":"Hysek","year":"2012","journal-title":"PLoS One"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.111.188425","article-title":"Effects of the 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.","volume":"340","author":"Hysek","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","article-title":"MDMA enhances mind reading of positive emotions and impairs mind reading of negative emotions.","volume":"222","author":"Hysek","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (ecstasy) in humans.","volume":"90","author":"Hysek","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/00952990903383961","article-title":"Atomoxetine attenuates dextroamphetamine effects in humans.","volume":"35","author":"Sofuoglu","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/clpt.2011.125","article-title":"A perhaps unexpected role of norepinephrine in actions of MDMA.","volume":"90","author":"Newton","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"e30854","DOI":"10.1371\/journal.pone.0030854","article-title":"2nd, Brown G, et al.Noradrenergic a1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial.","volume":"7","author":"Newton","year":"2012","journal-title":"PLoS One"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.pbb.2007.02.006","article-title":"alpha1-Adrenergic receptors mediate the locomotor response to systemic administration of ()-3,4-methylenedioxymethamphetamine (MDMA) in rats.","volume":"86","author":"Selken","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(02)02616-X","article-title":"Cocaine-induced hypophagia and hyperlocomotion in rats are attenuated by prazosin.","volume":"455","author":"Wellman","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1523\/JNEUROSCI.22-07-02873.2002","article-title":"alpha1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates.","volume":"22","author":"Drouin","year":"2002","journal-title":"J Neurosci"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00213-003-1509-8","article-title":"On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization.","volume":"169","author":"Vanderschuren","year":"2003","journal-title":"Psychopharmacology"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1523\/JNEUROSCI.18-07-02729.1998","article-title":"Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine.","volume":"18","author":"Darracq","year":"1998","journal-title":"J Neurosci"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1523\/JNEUROSCI.22-21-09150.2002","article-title":"D-Amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release.","volume":"22","author":"Auclair","year":"2002","journal-title":"J Neurosci"},{"key":"R19-11-20210128","first-page":"725","article-title":"Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission.","volume":"278","author":"Pan","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/npp.2010.42","article-title":"Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.","volume":"35","author":"Forget","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.biopsych.2005.02.003","article-title":"Prazosin, an a1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking.","volume":"57","author":"Zhang","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1192\/bjp.128.3.280","article-title":"The SCL-90 and the MMPI: a step in the validation of a new self-report scale.","volume":"128","author":"Derogatis","year":"1976","journal-title":"Br J Psychiatry"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1008931926181","article-title":"The Symptom Check-List-90-R (SCL-90-R): a German validation study.","volume":"9","author":"Schmitz","year":"2000","journal-title":"Qual Life Res"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0091-3057(02)00818-3","article-title":"Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase.","volume":"73","author":"White","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2125.1999.00067.x","article-title":"Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.","volume":"48","author":"Chung","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5551\/jat.3582","article-title":"Contradictory effects of beta1- and alpha1-aderenergic receptor blockers on Cardio-Ankle Vascular Stiffness Index (CAVI)CAVI independent of blood pressure.","volume":"18","author":"Shirai","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","article-title":"Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.","volume":"28","author":"Kolbrich","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.","volume":"323","author":"Farre","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"S2","key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV).","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/clpt.2009.62","article-title":"Cannabis coadministration potentiates the effects of ecstasy on heart rate and temperature in humans.","volume":"86","author":"Dumont","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bjp.0704094","article-title":"Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat.","volume":"133","author":"McDaid","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13105-011-0093-3","article-title":"Role of alpha adrenoceptors and nitric oxide on cardiovascular responses in acute and chronic hypertension.","volume":"67","author":"Hong","year":"2011","journal-title":"J Physiol Biochem"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-133-12-200012190-00012","article-title":"Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.","volume":"133","author":"Lester","year":"2000","journal-title":"Ann Intern Med"},{"key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0196-0644(85)80934-3","article-title":"Propranolol-induced hypertension in treatment of cocaine intoxication.","volume":"14","author":"Ramoska","year":"1985","journal-title":"Ann Emerg Med"},{"key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/emj.2009.079905","article-title":"Effects of a -blocker on the cardiovascular response to MDMA (ecstasy).","volume":"27","author":"Hysek","year":"2010","journal-title":"Emerg Med J"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/j.1476-5381.2012.01936.x","article-title":"Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.","volume":"166","author":"Hysek","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R41-11-20210128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/0002-9343(93)90212-8","article-title":"Influence of labetalol on cocaine-induced coronary vasoconstriction in humans.","volume":"94","author":"Boehrer","year":"1993","journal-title":"Am J Med"},{"key":"R42-11-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-3057(99)00201-4","article-title":"Effects of labetalol treatment on the physiological and subjective response to smoked cocaine.","volume":"65","author":"Sofuoglu","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0376-8716(00)80009-5","article-title":"Carvedilol affects the physiological and behavioral response to smoked cocaine in humans.","volume":"60","author":"Sofuoglu","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/026988110001400313","article-title":"The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (ecstasy) in healthy volunteers.","volume":"14","author":"Liechti","year":"2000","journal-title":"J Psychopharmacol"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130000648","article-title":"Gender differences in the subjective effects of MDMA.","volume":"154","author":"Liechti","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bjp.0705823","article-title":"Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced rhabdomyolysis with alpha1- plus beta3-adrenoreceptor antagonists.","volume":"142","author":"Sprague","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R47-11-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/426403a","article-title":"Pharmacology: uncoupling the agony from ecstasy.","volume":"426","author":"Mills","year":"2003","journal-title":"Nature"},{"key":"R48-11-20210128","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/01.CCM.0000165969.29002.70","article-title":"Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) in an animal model.","volume":"33","author":"Sprague","year":"2005","journal-title":"Crit Care Med"},{"key":"R49-11-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","article-title":"The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"189","author":"Tancer","year":"2007","journal-title":"Psychopharmacology"},{"key":"R50-11-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00213-002-1131-1","article-title":"Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"162","author":"Harris","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-11-20210128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0269881108094650","article-title":"Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.","volume":"23","author":"Hasler","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R52-11-20210128","doi-asserted-by":"crossref","first-page":"e40187","DOI":"10.1371\/journal.pone.0040187","article-title":"Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT(2) and 5-HT(1) receptors.","volume":"7","author":"van Wel","year":"2012","journal-title":"PLoS One"},{"key":"R53-11-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","article-title":"Psychological and physiological effects of MDMA (ecstasy) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.","volume":"23","author":"Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"R54-11-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","article-title":"Acute psychological and physiological effects of MDMA (ecstasy) after haloperidol pretreatment in healthy humans.","volume":"10","author":"Liechti","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"R55-11-20210128","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0091-3057(87)90618-6","article-title":"Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys.","volume":"26","author":"Woolverton","year":"1987","journal-title":"Pharmacol Biochem Behav"},{"key":"R56-11-20210128","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pharmthera.2012.01.010","article-title":"3rd, Newton TF, et al.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.","volume":"134","author":"Haile","year":"2012","journal-title":"Pharmacol Ther"},{"key":"R57-11-20210128","first-page":"3009","article-title":"Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines.","volume":"80","author":"Eisenhofer","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-11-20210128","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1152\/physrev.1990.70.4.963","article-title":"Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions.","volume":"70","author":"Esler","year":"1990","journal-title":"Physiol Rev"},{"key":"R59-11-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1152\/jappl.2001.90.1.121","article-title":"Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.","volume":"90","author":"Mazzeo","year":"2001","journal-title":"J Appl Physiol"},{"key":"R60-11-20210128","first-page":"1837","article-title":"Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension.","volume":"13","author":"Jacobs","year":"1995","journal-title":"J Hypertens"},{"key":"R61-11-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2125.2000.00121.x","article-title":"Non-linear pharmacokinetics of MDMA (ecstasy) in humans.","volume":"49","author":"de la Torre","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R62-11-20210128","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00000542-199108000-00013","article-title":"Central a1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an 2-adrenoceptor agonist.","volume":"75","author":"Guo","year":"1991","journal-title":"Anesthesiology"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182979d32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:01:52Z","timestamp":1620957712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201310000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182979d32","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}